- Home
- MYGN vs PROK Comparison
MYGN vs PROK Comparison
Compare MYGN & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYGN | PROK |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.9M | 331.2M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYGN | PROK |
|---|---|---|
| Price | $4.60 | $2.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $8.06 | $7.40 |
| AVG Volume (30 Days) | ★ 1.1M | 789.9K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | $76,000.00 |
| Revenue This Year | $7.26 | $1,010.19 |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.76 | $0.46 |
| 52 Week High | $11.44 | $7.13 |
Technical Indicators
Market Signals| Indicator | MYGN | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 37.54 | 56.52 |
| Support Level | $3.76 | $2.09 |
| Resistance Level | $5.66 | $2.58 |
| Average True Range (ATR) | 0.35 | 0.14 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 32.61 | 87.13 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.